The impact of COVID-19 pandemic on pediatric oncology

CellR4 2020; 8: e2854
DOI: 10.32113/cellr4_20205_2854

  Topic: COVID-19, Infectious Diseases     Category:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed an unprecedented threat to the global healthcare system. Children with cancer stand to be amongst the most vulnerable populations given their immunocompromised state and high reliance on hospital-based or clinic-based care 1. However, the true impact of COVID-19 infection on children with cancer remains unknown 2.

Emerging research suggests that adults with cancer and adult cancer survivors have a higher risk of SARS-CoV-2 infection (OR, 2.31; 95% CI, 1.89-3.02) 3 and more severe outcomes following SARS-CoV-2 infection (39% vs. 8%; Fisher’s exact p=0.0003) 4 than those without cancer. However, in these studies cancer patients were also more likely to be of older age, smokers, and have other comorbidities 3,4. While these additional risk factors do not apply to the pediatric oncology population, we can expect a similar or greater impact of COVID-19 due to the more myelosuppressive and immunosuppressive nature of pediatric cancer treatments 5. Nearly 90% of children with COVID-19 present with mild or moderate symptoms 6. However, in other coronaviruses, immunocompromised children are known to have more severe symptoms including life-threatening respiratory failure 7. Reports of post-transplant patients with COVID-19 suggest that T-cell immunosuppression predisposes patients to more severe outcomes 8,9. Even in previously healthy patients, severity of disease is correlated with T-cell lymphopenia 10.

This suggests that functional T-cells may be vital to control the COVID-19 infection 11.

Children with cancer are also susceptible to become indirect victims of the COVID-19 pandemic due to delayed diagnosis, limited access to care, interruptions in treatment, blood shortages, and suspensions of clinical trials for promising new therapies 12-15. A small case series of the Italian Pediatric Hospital Research Network described delayed presentations to the pediatric emergency room during a week at the height of the COVID-19 outbreak 12. Three of these patients had newly diagnosed cancers with extremely severe presentations, one dying within days of admission 12.

Regarding infection prevention, many have referred to the efforts of the pediatric hematology-oncology and transplant center in the Lombardy region in Northern Italy 16. Despite being embedded in a designated COVID-19 hospital within the most affected region in Italy, there were no reported positive cases of COVID-19 in pediatric hematology-oncology or transplanted inpatients 16. This was attributed to the implementation of aggressive anticipatory infection prevention measures. The crux of these measures were clear clinical leadership, limiting non-urgent admissions, isolating staff and patients from COVID-19 areas, nucleic acid testing for staff and patients prior to elective procedures and admissions (if symptomatic with a negative test, a second nasopharyngeal swab should be performed), supervised hand-washing and use of personal protective equipment (PPE), and restricting visitors 15,16. In the outpatient setting, many of these same measures were untaken, patient visits were managed remotely when possible [telemedicine], and strict patient isolation procedures were put into place 16,17.

Recently, leadership of the International Society of Pediatric Oncology (SIOP), Children’s Oncology Group (COG), St Jude Global program, Childhood Cancer International (CCI), and others came together to put forth a framework for caring for children with cancer during the COVID-19 pandemic 15. Although informed by collective expert opinion and not evidenced-based, these guidelines provide advice on adapting diagnostic and treatment protocols to protect children and healthcare workers 15. Overall, they recommend all children suspected of having a newly diagnosed malignancy undergo immediate workup and proceeding with treatment when possible 15.

If diagnostic modifications are necessary due to resource constraints (i.e. lack of flow cytometry and molecular diagnostics, neuroimaging, etc.), judgement should proceed based on available clinical information and testing 15. Similarly, there is no current evidence to support an elective reduction in cancer treatments15. However, if complex surgeries or radiotherapy are unavailable, administering chemotherapy prior to or in absence of these agents may be safe in children who meet the appropriate clinical criteria 15. Deferring elective high-risk treatments (such as cellular and stem cell therapies) may be important to patient safety and preserving hospital services 15,16.

These guidelines also acknowledge that the burden of this pandemic may inequitably fall on low- and middle-income countries (LMIC) and protocols should be modified based on regional resources 15. Pediatric oncology patients in LMIC face additional unique challenges of COVID-19 ranging from scarce financial resources, limited testing and PPE, drug shortages, and insufficient skilled healthcare professionals and hospital resources 18,19. Lack of government safety net programs 5,18,20, and suspended funding from non-governmental organizations (NGO) will exacerbate and prolong the burden of the COVID-19 pandemic in LMIC 21.

Due to a paucity of data of SARS-CoV-2 infection, a global COVID-19 childhood cancer registry has been established 15. This information will be vital to inform not only present decisions, but similar challenges in the future.

 

 

 

 

Funding:

The authors have no funding related to the content of this manuscript.

 

Acknowledgements:

The authors of this article have no conflicts of interest or financial interests to disclose. All authors have contributed to the manuscript in significant ways, have reviewed and agreed upon the manuscript content. This article is not under consideration at another journal.

 

Conflict of interest:

The authors declare that they have no conflict of interest to disclose.

 

References

  1. Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020; 17: 268-270.
  2. Bouffet E, Challinor J, Sullivan M, Biondi A, Rodriguez-Galindo C, Pritchard-Jones K. Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. Pediatr Blood Cancer 2020 Apr 2: e28327.
  3. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, JAMA Oncol 2020: e200980. doi: 10.1001/jamaoncol.2020.0980. Epub ahead of print.
  4. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He Cancer patients in SARS- CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-337.
  5. Kotecha RS. Challenges posed by COVID-19 to children with cancer. Lancet Oncol 2020; 21:
  6. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics 2020; doi: 10.1542/peds.2020-0702
  7. Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an immunocompromised state. J Pediatric Infect Dis Soc 2019; 8: 21-28.
  8. Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, Lin
  9. COVID-19 in posttransplant patients-report of 2 cases. Am J Transplant 2020 Apr 3. doi: 10.1111/ajt.15896. Epub ahead of print.
  10. Zhu L, Xu X, Ma K, Yang J, Guan H, Chen S, Chen Z, Chen G. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosupp Am J Transplant 2020 Mar 17:10.1111/ajt.15869. doi: 10.1111/ajt.15869. Epub ahead of print.
  11. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, Xiong L, Guo C, Tian J, Luo J, Yao J, Pang R, Shen H, Peng C, Liu T, Zhang Q, Wu J, Xu L, Lu S, Wang B, Weng Z, Han C, Zhu H, Zhou R, Zhou H, Chen X, Ye P, Zhu B, He S, He Y, Jie S, Wei P, Zhang J, Lu Y, Wang W, Zhang L, Li L, Zhou F, Wang J, Dittmer U, Lu M, Hu Y, Yang D, Zheng X. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020; 02.16.20023671.
  12. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020 Apr 28:1-12. doi: 10.1038/s41577-020-0311-8. Epub ahead of print.
  13. Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health 2020; 4: e10-e1.
  14. Saini KS, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, Saini ML, Verma S, Leone M, Aftimos P, Curigliano G. Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol 2020 Apr 24: S2352-3026(20)30123-X. doi: 1016/ S2352-3026(20)30123-X. Epub ahead of print.
  15. World Health Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (‎COVID-19)‎: interim guidance, 20 March 2020. Geneva: World Health Organization 2020.
  16. Sullivan M, Bouffet E, Rodriguez-Galindo C, Luna-Fineman S, Khan MS, Kearns P, Hawkins DS, Challinor J, Morrissey L, Fuchs J, Marcus K, Balduzzi A, Basset-Salom L, Caniza M, Baker JN, Kebudi R, Hessissen L, Sullivan R, Pritchard-Jones K. The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Pediatr Blood Cancer 2020; e28409. doi: 10.1002/pbc.28409. Epub ahead of print. PMID: 32400924.
  17. Balduzzi A, Brivio E, Rovelli A, Rizzari C, Gasperini S, Melzi ML, Conter V, Biondi A. Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Estote parati. Bone Marrow Transplant 2020 Apr 20:1–6. doi: 10.1038/s41409-020-0895-4. Epub ahead of print.
  18. Hollander JE, Carr Virtually Perfect? Telemedicine for Covid-19. N Engl J Med 2020; 382: 1679-1681.
  19. Kugbey N, Ohene-Oti N, Vanderpuye COVID-19 and its ramifications for cancer patients in low-resource settings: Ghana as a case study. Ecancermedicalscience 2020 Apr 20; 14: ed99.
  20. Hopman J, Allegranzi B, Mehtar Managing COVID-19 in low- and middle-income countries. JAMA 2020; 323: 1549-1550.
  21. Saroha M, Moulik N. COPING with CORONA: a developing country perspective on managing children with cancer during COVID-19 pandemic. Cancer Research, Statistics, and Treatment 2020; 3: 97-101.
  22. Responding to Coronavirus/COVID-19. Available at: https://www.worldchildcancer.org/responding-coro- naviruscovid-19. (Accessed May 3 2020).

To cite this article

The impact of COVID-19 pandemic on pediatric oncology

CellR4 2020; 8: e2854
DOI: 10.32113/cellr4_20205_2854

Publication History

Submission date: 12 May 2020

Revised on: 18 May 2020

Accepted on: 26 May 2020

Published online: 27 May 2020